Intra-Cellular Therapies

OverviewSuggest Edit

Intra-Cellular Therapies is a biopharmaceutical company that is developing novel drugs for the treatment of diseases and disorders of the Central Nervous System (CNS). The Company develops compounds that have the potential to treat a wide range of diseases associated with the central nervous system. Intra-Cellular Therapies is developing its lead drug candidate, lumateperone, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, depression, and other neuropsychiatric and neurological disorders.

TypePublic
Founded2002
HQNew York, US
Websiteintracellulartherapies.com

Latest Updates

Employees (est.) (Feb 2019)73(+49%)
Revenue (FY, 2017)$245.8 K(-25%)
Share Price (Jun 2019)$11 (-2%)

Key People/Management at Intra-Cellular Therapies

Sharon Mates

Sharon Mates

Founder, Chairman & Chief Executive Officer
Andrew Satlin

Andrew Satlin

Executive Vice President and Chief Medical Officer
Michael Halstead

Michael Halstead

Senior Vice President and General Counsel
Kimberly E. Vanover

Kimberly E. Vanover

Senior Vice President of Clinical Development
Robert E. Davis

Robert E. Davis

Senior Vice President, Chief Scientific Officer
Allen A. Fienberg

Allen A. Fienberg

Founder & Vice President of Business Development
Show more

Intra-Cellular Therapies Office Locations

Intra-Cellular Therapies has an office in New York
New York, US (HQ)
430 E 29th St #900
Show all (1)

Intra-Cellular Therapies Financials and Metrics

Intra-Cellular Therapies Revenue

Intra-Cellular Therapies's revenue was reported to be $245.84 k in FY, 2017
USD

Net income (FY, 2018)

(155.1m)

EBIT (FY, 2018)

(162.3m)

Market capitalization (10-Jun-2019)

606.5m

Closing stock price (10-Jun-2019)

11.0

Cash (31-Dec-2018)

54.9m
Intra-Cellular Therapies's current market capitalization is $606.5 m.
Annual
USDFY, 2013FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

2.7m2.7m577.3k91.4k330.7k245.8k

Revenue growth, %

(79%)(84%)262%

General and administrative expense

6.0m10.3m18.2m24.8m23.7m30.1m

R&D expense

23.0m21.2m87.7m93.8m79.4m132.2m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Revenue

668.0k167.8k219.2k124.4k3.3k57.4k124.4k3.3k228.4k4.4k95.3k114.7k30.8k

General and administrative expense

1.3m1.9m2.1m2.6m3.8m4.0m3.9m5.1m6.5m6.3m6.3m6.3m5.3m6.4m13.1m

R&D expense

4.2m2.8m2.7m4.0m18.6m17.8m28.5m23.4m25.3m23.9m21.5m12.5m18.5m30.7m63.1m

Operating expense total

5.5m4.7m4.8m6.6m22.4m21.7m32.3m28.5m31.8m30.2m27.8m18.7m23.8m37.1m76.3m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

35.2m61.3m47.2m48.6m37.8m54.9m

Accounts Receivable

336.3k51.6k30.7k94.3k

Inventories

762.2k1.3m8.0m4.0m

Current Assets

38.2m131.0m483.3m388.2m469.2m355.4m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

44.1m143.6m91.1m68.9m100.8m71.4m332.8m37.2m52.0m200.4m23.6m29.6m52.3m74.4m69.8m

Accounts Receivable

251.3k167.8k219.2k124.4k3.3k9.1k51.6k98.2k1.3k68.2k61.9k6.3k

Current Assets

47.1m146.4m141.2m137.5m236.5m212.6m512.3m462.9m446.8m541.8m371.6m348.8m333.4m443.2m409.7m

PP&E

75.7k65.1k63.9k57.4k559.7k722.1k785.5k731.4k718.7k677.7k605.7k628.9k679.6k1.3m1.3m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(26.9m)(30.7m)(104.8m)(116.4m)(97.8m)(155.1m)

Depreciation and Amortization

23.2k25.5k139.6k196.9k213.9k368.7k

Inventories

Accounts Payable

3.4m(1.3m)(419.9k)2.1m2.4m7.8m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

(4.9m)(4.5m)(9.1m)(6.4m)(22.3m)(43.8m)(32.2m)(27.8m)(58.7m)(88.9m)(26.9m)(44.7m)(67.6m)(35.5m)(72.9m)

Depreciation and Amortization

6.3k12.7k47.1k48.0k96.7k146.8k50.4k101.8k155.3k82.5k178.3k

Accounts Payable

(1.3m)(3.0m)503.9k4.6m2.9m705.0k326.4k2.3m3.8m3.4m(2.0m)653.0k3.9m(794.7k)

Cash From Operating Activities

(7.0m)(12.2m)(46.7m)(19.7m)(33.1m)(62.8m)(16.4m)(41.3m)(55.7m)(27.0m)(60.6m)
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics

Intra-Cellular Therapies Operating Metrics

FY, 2017

Patents and Patent Applications

80
Show all operating metrics

Intra-Cellular Therapies Revenue Breakdown

Embed Graph

Intra-Cellular Therapies revenue breakdown by business segment: 33.6% from License and collaboration revenue and 66.4% from Grant Revenue

Intra-Cellular Therapies Online and Social Media Presence

Embed Graph

Intra-Cellular Therapies News and Updates

Intra-Cellular Therapies Provides Lumateperone Regulatory Update

FDA has informed the Company it has no plans to schedule an Advisory Committee Meeting

Intra-Cellular Therapies Provides Corporate Update and Reports Second Quarter 2019 Financial Results

NEW YORK, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today provided a corporate update and announced its financial results for the second quarter…

Intra-Cellular Therapies Provides Update on FDA Advisory Committee Meeting for Lumateperone for the Treatment of Schizophrenia

NEW YORK, July 23, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has cancelled the Psychophar…

Intra-Cellular Therapies stock down 15% after disappointing Phase 3 trial results

Shares of biotech Intra-Cellular Therapies fell 15% in premarket trade Monday after the company announced disappointing results from a late-stage trial of its lead drug candidate lumateperone, a potential bipolar depression treatment. The trial, which evaluated 554 patients with bipolar disorder in…

Intra-Cellular Therapies Announces FDA Advisory Committee Meeting to Review the NDA for Lumateperone for the Treatment of Schizophrenia in Adults

NEW YORK, June 13, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that the  U.S. Food and Drug Administration (FDA) has announced a Psychopharm…

Intra-Cellular Therapies Reports First Quarter 2019 Financial Results and Provides Corporate Update

NEW YORK, May 08, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the first quarter ended March 31, 2019, and provide…
Show more

Intra-Cellular Therapies Blogs

Intra-Cellular Therapies to Present at the Canaccord Genuity 39th Annual Growth Conference

Intra-Cellular Therapies to Present at the Canaccord Genuity 39th Annual Growth Conference Content Import Tue, 08/06/2019 - 08:02 Intra-Cellular Therapies to Present at the Canaccord Genuity 39th Annual Growth Conference Aug 6, 2019 This release is a backfill …

Intra-Cellular Therapies to Host Conference Call to Provide Regulatory Update Following Recent Meeting with FDA

Agreement reached with FDA on submission of additional non-clinical information for NDA review of lumateperone for the treatment of schizophrenia Lumateperone PDUFA goal date extended three months to December 27, 2019 Conference call scheduled today at 8:30 am ET NEW YORK , Aug.

Intra-Cellular Therapies Announces Positive Top-line Results from a Phase 3 Trial of Lumateperone in Patients with Bipolar Depression

Intra-Cellular Therapies Announces Positive Top-line Results from a Phase 3 Trial of Lumateperone in Patients with Bipolar Depression Content Import Mon, 07/08/2019 - 07:01 Intra-Cellular Therapies Announces Positive Top-line Results from a Phase 3 Trial of Lumateperone in Patients with Bi…

Intra-Cellular Therapies Appoints Karen Patruno Sheehy, Esq. as Senior Vice President, Chief Compliance Officer

Intra-Cellular Therapies Appoints Karen Patruno Sheehy, Esq. as Senior Vice President, Chief Compliance Officer Content Import Tue, 07/02/2019 - 08:02 Intra-Cellular Therapies Appoints Karen Patruno Sheehy, Esq. as Senior Vice President, Chief Compliance Officer Jul 2, 2019 …

Intra-Cellular Therapies to Present at JMP Securities Life Sciences Conference

Intra-Cellular Therapies to Present at JMP Securities Life Sciences Conference Content Import Wed, 06/19/2019 - 08:01 Intra-Cellular Therapies to Present at JMP Securities Life Sciences Conference Jun 19, 2019 This release is a backfill from a News Wire …

Intra-Cellular Therapies Frequently Asked Questions

  • When was Intra-Cellular Therapies founded?

    Intra-Cellular Therapies was founded in 2002.

  • Who are Intra-Cellular Therapies key executives?

    Intra-Cellular Therapies's key executives are Sharon Mates, Andrew Satlin and Michael Halstead.

  • How many employees does Intra-Cellular Therapies have?

    Intra-Cellular Therapies has 73 employees.

  • Who are Intra-Cellular Therapies competitors?

    Competitors of Intra-Cellular Therapies include Kineta, Allergan and ARMO BioSciences.

  • Where is Intra-Cellular Therapies headquarters?

    Intra-Cellular Therapies headquarters is located at 430 E 29th St #900, New York.

  • Where are Intra-Cellular Therapies offices?

    Intra-Cellular Therapies has an office in New York.

  • How many offices does Intra-Cellular Therapies have?

    Intra-Cellular Therapies has 1 office.